DIFFUSE LARGE B-CELL LYMPHOMA

This study tests whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (DA-REPOCH) can help people with aggressive B-cell non-Hodgkin lymphoma. About 30 adults with advanced stages of the disease will receive the combination, followed by a short cours…

This study tests a personalized approach for people with a type of blood cancer called diffuse large B-cell lymphoma. Doctors use special blood tests (ctDNA) and PET scans after two rounds of standard chemo to decide if treatment should be adjusted—either stronger or milder. The …

This study tests a new drug called parsaclisib added to standard chemotherapy (R-CHOP) for people with newly diagnosed, high-risk diffuse large B-cell lymphoma. The goal is to find the safest dose and see if the combination improves treatment response. About 50 adults will take p…

This study tests a new drug combination for people with aggressive types of lymphoma that haven't been treated yet. The treatment adds a targeted drug called polatuzumab vedotin to standard chemotherapy. The goal is to see if this combo can make more cancers disappear completely.…

This study tests if adding brentuximab vedotin to two standard drugs (lenalidomide and rituximab) helps people with a type of blood cancer called diffuse large B-cell lymphoma that has returned or not responded to prior treatments. About 239 adults will receive either the new dru…

This study tests whether adding the drug venetoclax to standard chemotherapy can help prevent high-grade B-cell lymphomas from returning or getting worse. About 363 adults with specific aggressive lymphoma types will receive either the usual chemo or the usual chemo plus venetocl…

This study tests whether adding the drug vorinostat to standard care can lower the chance of graft-versus-host disease (GVHD) in children, teens, and young adults getting a bone marrow or blood stem cell transplant for blood cancers. About 43 participants will receive vorinostat …

This early-phase study tests a combination of two drugs, copanlisib and nivolumab, in people with certain types of blood cancer that have changed into a more aggressive form (Richter's transformation or transformed non-Hodgkin lymphoma). The goal is to find the best dose and see …

This early-phase trial is testing whether adding the targeted drug zanubrutinib to standard chemotherapy (R-PolaCHP) is safe and effective for people with newly diagnosed diffuse large B-cell lymphoma. About 38 adults will take part. The goal is to find the best dose and watch fo…

This study tests a combination of two drugs, copanlisib and venetoclax, in people with diffuse large B-cell lymphoma that has come back or not responded to prior treatments. The goal is to find the safest dose and see how well the drugs shrink tumors. About 48 adults will take pa…

This study tests whether adding the experimental drug glofitamab to standard chemotherapy (gemcitabine plus oxaliplatin) helps people with relapsed or refractory diffuse large B-cell lymphoma live longer compared to the usual treatment (rituximab plus same chemo). About 270 adult…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (R-ICE) helps people with diffuse large B-cell lymphoma whose cancer has come back or not responded to earlier treatment. About 65 adults will take part. The main goal is to see if the c…

This study tests a new drug called MT-2111 in people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors. The trial involves 46 …

This study tests an experimental drug called DZD8586 in about 59 adults with diffuse large B-cell lymphoma that has returned or stopped responding to prior treatment. The goal is to see if the drug can shrink tumors and to understand its side effects. Participants take the drug a…

This study tests a new drug called epcoritamab (given as a shot under the skin) against standard chemotherapy for people with diffuse large B-cell lymphoma that has returned or not responded to treatment. About 483 adults who cannot have a stem cell transplant will be randomly as…

This study tests a new treatment called rapcabtagene autoleucel (YTB323) for adults with several types of blood cancer, including chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. The treatment uses a patien…

This study tests whether giving a drug called E7777 before standard CAR-T cell therapy can help people with relapsed or hard-to-treat large B-cell lymphoma. About 30 participants will receive E7777 followed by chemotherapy and an approved CAR-T product. The goal is to find the sa…

This study tests a modified dosing schedule of the drug tafasitamab given together with lenalidomide in adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. Participants must have had 1 to 3 prior treatments and cannot have a stem cell…

This study tests an experimental radioactive drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphoma) that have come back or not responded to standard treatments. The drug is designed to target and kill…

This study tests whether adding two drugs, tafasitamab and lenalidomide, to standard chemotherapy (R-CHOP) helps people with a fast-growing type of lymphoma called DLBCL. About 900 patients with high-risk disease are taking part. The goal is to see if the new combination keeps ca…

This study tests whether giving a mix of targeted drugs (rituximab, lenalidomide, acalabrutinib, tafasitamab) before and with standard chemotherapy can better control a fast-growing type of lymphoma called DLBCL. About 62 adults with newly diagnosed disease will participate. The …

This study tests a combination of two drugs, tafasitamab and lenalidomide, in adults with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to previous treatments. Participants must have had 1 to 3 prior treatments and cannot have a s…

This study tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has come back or not responded to treatment. The goal is to find the safest dose and see if the drug can shrink tumors. The study has two parts: first, finding the right dose, then te…

This study looks at a new way of giving standard chemotherapy (R-CHOP) to older adults aged 75 and up with diffuse large B-cell lymphoma. The goal is to see if splitting the doses makes treatment easier to tolerate while still being effective. About 27 participants will receive t…

This study tests a new drug called epcoritamab (given as a shot under the skin) against standard chemotherapy for people with diffuse large B-cell lymphoma that has come back or stopped responding to treatment. About 72 adults in China who cannot have a stem cell transplant will …

This study looks at whether giving vitamin D to cancer patients who are low in it can help them live longer without their disease getting worse. About 565 adults with certain lymphomas or leukemia will either get vitamin D or no extra vitamin D. The goal is to see if vitamin D re…

This study is for Japanese adults with Non-Hodgkin lymphoma, a type of blood cancer. Researchers are testing a drug called tafasitamab, alone or combined with other medicines (lenalidomide, parsaclisib, or R-CHOP chemotherapy), to see if it is safe and helps shrink tumors. The st…

This study tests a new combination of drugs (epcoritamab plus lenalidomide) against a standard chemotherapy regimen for adults with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. About 379 participants will be randomly assigned to one of thre…

This study tests whether adding the targeted drug acalabrutinib to standard chemotherapy (R-CHOP) helps people with untreated diffuse large B-cell lymphoma live longer without the cancer growing. About 450 adults will receive one cycle of R-CHOP, then two-thirds will also take ac…

This study tests whether adding the drug acalabrutinib to standard chemotherapy (R-CHOP) helps people with a certain type of untreated diffuse large B-cell lymphoma (non-GCB DLBCL). About 611 adults aged 18 to 75 are participating. The main goal is to see if the combination delay…

This study tests adding an experimental drug called selinexor to the standard chemotherapy R-CHOP for people with B-cell non-Hodgkin lymphoma. The goal is to find the safest dose and see if the combination works better than standard treatment alone. About 43 adults with advanced …

This early-phase study tests a new drug called ABBV-525 in people with B-cell cancers like lymphoma and leukemia. The goal is to check safety and find the best dose. About 78 adults will take the drug by mouth at different dose levels over up to 64 months.

This early-stage study tests a new drug called IMT-009 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose and learn about side effects. About 67 participants will receive the drug intravenously,…

This study tests a personalized treatment where a child's own immune cells are modified in a lab to recognize and attack cancer cells that have a protein called CD19. It is for children and young adults with certain types of leukemia or lymphoma that have come back or not respond…

This study tests a drug called epcoritamab, given alone or with lenalidomide, in elderly patients with a type of lymphoma (DLBCL) who cannot receive standard chemotherapy due to age or health issues. About 111 participants will receive active treatment, and researchers will measu…

This study tests a new drug called GNC-038 in 12 adults with diffuse large B-cell lymphoma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. It is an early-phase trial to gather …

This study tests an experimental drug called selinexor in adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who have run out of standard treatments. The main goal is to see how many patients respond to the drug. About 244 participants will …

This study tests an investigational drug called epcoritamab, given alone or with other standard treatments, in about 543 people with B-cell non-Hodgkin lymphoma. The goal is to find the best dose and see how well it shrinks tumors. Participants receive active treatment; no one ge…

This study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants…

This study looks at whether giving a lower dose of radiation to people with diffuse large B-cell lymphoma (a type of blood cancer) can still keep the cancer from coming back while causing fewer side effects. About 241 participants who had a clear PET scan after chemotherapy will …

This study collects white blood cells from people with leukemia or lymphoma whose cancer has not been cured by standard treatments. The cells are stored and may later be used to create a personalized therapy called CAR T-cells. The goal is to make it easier for patients to get th…

This study tests a nanochip technology to see if it can better monitor how well treatment is working and detect if lymphoma comes back in people with diffuse large B-cell lymphoma. About 73 participants will provide blood samples during their standard chemotherapy. The goal is to…

This study looks at whether a blood test can quickly detect leftover cancer DNA in people treated with CAR-T cells for a type of lymphoma. About 40 adults will provide blood samples a week after treatment, and researchers will see if they can report results within three weeks. Th…

This study tracks about 50 people who previously received an experimental CAR T cell therapy for several types of lymphoma. The goal is to watch for long-term side effects and check how well patients do over 15 years. No new treatment is given, but patients can receive other canc…

This study looks at whether training doctors to communicate better can help lymphoma patients move from active treatment to survivorship. It involves 314 patients with Hodgkin's or Diffuse Large B-cell Lymphoma and their doctors. The goal is to improve how doctors discuss follow-…

This study follows about 1,000 Chinese adults with diffuse large B-cell lymphoma (DLBCL) to see how well the drug polatuzumab works in real-world hospital settings. Researchers will track how long patients live without their cancer getting worse, focusing on three groups: frail/o…